How Augle's multi-agent ensemble serves CMOs, pharmacy committees, and clinical development leaders — from technology adoption reviews to trial design validation. Each session shows how structured deliberation surfaces safety signals, evidence gaps, and protocol weaknesses before they become costly downstream problems.
Each session below shows the complete arc: question submitted, ensemble behaviour across agents, unresolved objections preserved verbatim, and the session output.
“Does the published evidence support adopting AI-assisted colonoscopy detection as standard of care, and what are the unresolved safety and efficacy questions before system-wide rollout?”
Settled: AI-assisted colonoscopy (CADe) significantly increases adenoma detection rate (ADR) — meta-analyses show 10–15 percentage point ADR improvement. Contested: whether increased ADR translates to reduced colorectal cancer incidence — this requires longer-term follow-up data not yet available. Unknown: whether ADR improvement represents true cancer prevention or detection of clinically insignificant lesions (the overdiagnosis question).
Surrogate endpoint problem: all major CADe trials use ADR as the primary endpoint. ADR is a validated surrogate for colonoscopy quality but not a direct measure of cancer prevention. The FDA approved CADe devices based on ADR improvement alone. Whether ADR improvement from AI assistance confers the same cancer prevention benefit as ADR improvement from other quality interventions is not established.
“The overdiagnosis risk is being systematically underdiscussed. AI detection is optimised for sensitivity, not specificity. Increased ADR from AI assistance includes a disproportionate increase in detection of diminutive lesions (<5mm) whose malignant potential is low and whose removal carries procedural risk. One health system that adopted CADe system-wide saw post-polypectomy bleeding rates increase 23% without a corresponding reduction in interval cancers.”
Confidence: Probable that CADe improves ADR. Contested whether ADR improvement prevents cancer at population scale. Gap on overdiagnosis and diminutive lesion removal risk. Clinical recommendation: pilot with post-polypectomy complication monitoring and 3-year interval cancer tracking before system-wide rollout.
“What does the evidence base establish about the comparative effectiveness of GLP-1 agonists vs. bariatric surgery for long-term weight maintenance in patients with BMI 35–40, and what does the formulary decision need to account for?”
Settled: both GLP-1 agonists (semaglutide 2.4mg) and bariatric surgery produce substantial weight loss at 1 year. Contested: long-term (5-year+) weight maintenance comparison — surgery data extends to 10 years; GLP-1 data extends only to 4 years. Unknown: whether GLP-1 agonist efficacy is sustained if medication is discontinued; available discontinuation data shows significant weight regain.
Comparison validity: head-to-head RCT data comparing GLP-1 to surgery does not exist. Available evidence is observational or indirect comparison. The populations in surgery trials and GLP-1 trials differ systematically in comorbidity burden, which confounds any indirect comparison. A formulary decision that treats indirect comparison evidence as equivalent to RCT evidence will be methodologically contested.
“The discontinuation data is the critical factor the committee is not fully weighing. If GLP-1 therapy requires indefinite continuation to maintain effect — which the current evidence suggests — the formulary decision is not a one-time cost comparison. It is a commitment to indefinite high-cost medication for a chronic condition. The lifetime cost comparison changes the recommendation entirely.”
Formulary framing: present this as a treatment pathway decision, not a cost comparison. For BMI 35–40 without metabolic comorbidity: GLP-1 trial with explicit discontinuation protocol. For BMI 35–40 with comorbidity (T2D, hypertension): surgery referral pathway with GLP-1 as bridge. Document decision criteria explicitly so the P&T committee can revisit when 5-year GLP-1 maintenance data is available.
“Does the proposed adaptive trial design for our Phase 2b oncology study meet the evidentiary standards that FDA will require for accelerated approval consideration, and where are the protocol weaknesses?”
Settled: FDA has approved adaptive designs for oncology trials and published guidance on acceptable interim analysis frameworks (2019 guidance). Contested: whether the specific response rate threshold used as the adaptive interim decision rule meets the Type I error control standard FDA has applied in recent complete response letters. Unknown: whether the proposed biomarker endpoint will be accepted as a primary endpoint or relegated to secondary given the current oncology endpoint precedent.
Type I error inflation risk: the proposed design uses three interim analyses with alpha spending allocated equally across interim looks. FDA's recent feedback in analogous trials has indicated preference for O'Brien-Fleming or Lan-DeMets alpha spending, not equal allocation. Equal allocation inflates Type I error at early interim analyses when sample sizes are small. This is a protocol weakness that will appear in FDA pre-submission feedback.
“The biomarker endpoint is the higher-priority problem. The proposed primary endpoint (biomarker response rate at 12 weeks) is not an established surrogate for overall survival in this indication. FDA has accepted this biomarker as secondary in three recent approvals but has not accepted it as a primary endpoint for accelerated approval in any oncology programme in this tumour type. This needs a pre-IND meeting to resolve before the design is finalised.”
Protocol strength: adaptive design is generally sound. Two pre-submission requirements: (1) switch to O'Brien-Fleming alpha spending or provide statistical justification for equal allocation. (2) Request pre-IND meeting specifically on biomarker endpoint acceptability as primary before finalising the SAP.
The full solutions page for this vertical — problem framing, configuration panel, and why Augle for clinical research.
View solutions page →Clinical evidence review and technology readiness assessment — adjacent workflows for life sciences R&D teams.
View Research labs hub →Pre-publication review and systematic review gap analysis — adjacent workflows for academic medical centres.
View Universities + academia hub →Join the waitlist and get one Standard session free — real deliberation, not a simulation.